Similarly, another phase II trial (NCT05242965) is testing the vaccine in non-small cell lung cancer (NSCLC) to assess its versatility across epithelial cancers, often in combination with GM-CSF as an adjuvant to boost immune cell recruitment and activation [136]. This evidence concerns the gene CSF2 and non-small cell lung carcinoma.